

**REMARKS**

Claim 14 has been amended and claims 1-13 and 15-24 are canceled. New claims 25-41 are being added. The amended claim and newly added claims do not add new matter and are completely supported by the application as originally filed. More particularly, support for the amendment to claim 14 may be found, for example, on page 6, line 24 through page 7, line 2. Support for claims 25 and 26 may be found, for example, on page 3, lines 6-7. Support for claims 27-38 may be found, for example, on page 14, lines 11-28 and page 51, lines 4-19. Support for claims 39 and 40 may be found, for example, on page 8, line 18 through page 14, line 28 and page 51, lines 4-19. Support for claim 41 may be found, for example, on page 2, lines 22-25.

Amendments to the claims are made without prejudice to the pending or now canceled claims or to any subject matter pursued in related applications. Applicants reserve the right to prosecute any canceled subject matter at a later time or in a later filed divisional, continuation or continuation-in-part application.

Upon entry of the amendments, claims 14 and 25-41 are pending in the instant application. Attached hereto as Appendix I is a marked up version of the amended claim indicating the changes made. The commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-1271, under Order No. R-741.

Respectfully submitted,

Date: November 25, 2002

  
Aaron T. Hokamura (Reg. No. 51,810)

DELTAGEN, INC.  
740 Bay Road  
Redwood City, CA 94063  
(650) 569-5100

Enclosures

**APPENDIX I**

**Version With Markings To Show Changes Made**

(Deletions are indicated by brackets; Insertions are indicated by underline)

In the claims:

14. (Amended)        A transgenic mouse comprising a disruption in an endogenous RPTPB gene, wherein there is no native[significant] expression of endogenous[the] RPTPB[ gene in the transgenic mouse].